Glargine-300: An updated literature review on randomized controlled trials and real-world studies

作     者：Sujoy Ghosh Romik Ghosh 

作者机构：Department of EndocrinologyIPGME&RKolkata 700020West BengalIndia Medical AffairsSanofiMumbai 400072MaharashtraIndia 

出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)

年 卷 期：2020年第11卷第4期

页      面：100-114页

核心收录：

学科分类：1002[医学-临床医学] 081704[工学-应用化学] 07[理学] 08[工学] 0817[工学-化学工程与技术] 070303[理学-有机化学] 0703[理学-化学] 

主　　题：Insulin Glargine-300 Type 2 diabetes Diabetes mellitus Hypoglycaemia Glycaemic control 

摘      要：Despite the availability of a variety of insulins,rates of insulinisation and the acceptance of insulin therapy is suboptimal in real-world clinical *** and physician concerns with hypoglycaemia and weight gain are the two key issues that serve to impede appropriate insulinisation in patients with *** introduced second-generation basal insulin analogues [for e.g.,insulin glargine 300 U/m L(Gla-300) and insulin degludec] are designed to have improved pharmacokinetic profiles with an intention to deliver steady insulin levels over a longer *** randomised controlled and real-world studies have proven the resultant advantages of second-generations insulin analogues in lowering intra-individual variability in plasma insulin levels,flexibility in dosing,a sustained glucose-lowering effect,and decreasing the risk of ***-300 is one of the newer second-generation basal insulin analogues to have been approved for both type 1 and 2 *** this article,we review the currently available clinical and real-world data of Gla-300.